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In  the  last  two  decades,  several  randomized  clinical  trials
have  shown  superiority  of  catheter  ablation  over  antiar-
rhythmic  drugs  therapy  to  achieve  sinus  rhythm  and to
improve  symptoms  and quality  of  life  in paroxysmal  and
persistent  atrial  fibrillation  (AF)  patients.1,2 Since  the  first
demonstrations  that  pulmonary  veins  isolation  (PVI)  could
prevent  AF  initiation,  catheter  ablation  of  AF  has evolved
from  an  experimental  procedure  to  a  standard  rhythm  con-
trol  strategy  for patients  with  symptomatic  recurrent  AF,  and
may  be  appropriate  to perform  even  as  first-line  therapy.3
Despite  progresses  in  the  management  of  patients  with  AF,
the  prevalence  of  this  arrhythmia  in increasing  worldwide
and  it  remains  one of  the  major  causes  of  stroke,  heart  fail-
ure  and  cardiovascular  morbidity,  representing  a substantial
health  burden  for  patients  and  societies.
Catheter  ablation  of AF  is  now  commonly  used and  is
increasing  markedly  as  a real  clinical  option  for  the  treat-
ment  of  this  complex  arrhythmia,  representing  around  30%
of  all  ablations  performed  in  Portugal.4 However,  AF recur-
rence  can  occur  in  20-40%  of the patients  in the  first
year,  requiring  an additional  catheter  ablation.  For  per-
sistent  AF,  the  situation  seems  less  clear,  as the  evidence
base  is  weaker.5 Differences  in the  success  rates  are  likely
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related  to  a  more  complex  substrate  in  persistent  (and
long-standing  persistent)  AF,  and  with  the fact that the
electrical,  autonomic  and  structural  changes  related  to  the
atrial  remodeling  phenomena  promote  the  maintenance  of
AF,  contributing  to  the  resistance  to  sinus  rhythm  conversion
and  to AF recurrences.6,7 More  advanced  AF  is,  therefore,
more  difficult  to  treat  with  simple  catheter  ablation.  Nev-
ertheless,  around  40%  of  the  procedures  performed  are
reported  to  be  for  patients  with  persistent  type  of  AF.8 This
remind  us that  the optimal  ablation  technique  is  still  to  be
elucidated,  particularly  for  the treatment  of persistent  AF.
A  lot has  changed  in AF  ablation.  Knowledge  regarding
patients  selection  and follow-up,  new  catheters,  contact-
force  tools,  3D  mapping  systems  allowing  high-resolution
electrical  analysis,  integrating  imaging,  type of  energy  used
and  different  technical  approaches  have  evolved  over  the
past  years,  reflecting  the  integration  of multidisciplinary
input  of expert  cardiologists,  cardiac  surgeons,  electrophys-
iologists  and  engineering  teams.  However,  this  is  a  complex
intervention  with  potential  major  complications  and  with
risk  of  arrhythmia  recurrences,  frequently  occurring  in sub-
jects  with  PV  electrical  reconnection.9 Therefore,  there  is
consensus  among  experts  that  all  patients  undergoing  AF
ablation  should  be seen  in  follow-up  regularly  after  the  abla-
tion  procedure  in order  to  recognize  potential  complications
and  optimize  outcome  results.10
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Looking  to  the future is  something  that can be  seen  in
the  long  journey  of  those  who  always  keep  trying  to  find
the  right  pathway.  This  special  edition  of  the Portuguese
Journal  of  Cardiology  marks  the first  Portuguese  20 years  of
AF  ablation  based  on  PV isolation,11 and  represents  a  pure
exercise  of integration,  while  taking  the  experience  of  var-
ious  specialists  which have  been  contributing  to  improve
the  mechanistic  understanding,  as  well  as  technological
advances,  in  the  management  of AF.
Understanding  the role  of  localized  sources, like  foci
and  rotational  activity,  in the  maintenance  of AF, and map-
ping  it  using  innovative  technologies  in order  to  increase
the  success  of  AF  ablation,  represents  a continuous  chal-
lenge  in  this  field,  discussed  by  Narayan  et  al.,  and Carlo
Pappone  in  this  issue  of  the Journal.12,13 Also,  different  tech-
nical  approaches  may  contribute  to  improve  the efficacy
and  safety  of ablation,  particularly  concerning  persistent  AF.
Therefore,  this  issue  of  the Portuguese  Journal  of  Cardiol-
ogy  also  includes  extensive  data  about  the advantages  and
drawbacks  of  cryoballoon  ablation,14 substrate  modification,
based  on  isolation  of  atrial  fibrotic  areas,15 and  complete
isolation  of  the left atrial  appendage.16 In order  to  reduce
risks  of  this  complex  interventional  procedure,  experienced
operators  must  share  their  strategies  regarding  important
rules  to avoid  complications,  and,  of  course,  to  identify
and  manage  it  adequately  following  AF  ablation.  Professor
Mauricio  Scanavacca  explores  this  important  subject  in an
interesting  review  article.17
New  information  is  continually  generated  and  published,
in  accordance  with  a  substantial  progress  and  development
in  this  field.  Investigations  have  clarified  several  issues,
but  the  complexity  of the mechanisms  participating  in the
pathophysiology  of  AF  disease  makes  this task  an extremely
difficult  challenge  to  overcome.
Current  medical  guidelines  recommend  catheter  ablation
as  part  of  the management  strategy  in patients  with  AF,
being  a  first  option  treatment  in selected  patients.3 Pro-
gression  from  paroxysmal  AF  to  persistent  AF  appears  to  be
delayed  by  early  PVI.  This  provides  the rationale  for  the
ability  to  modify  the arrhythmogenic  substrate  of AF  and
addresses  the question  of  the best  timing  for ablation  in
patients  with  recent  paroxysmal  episodes.
Identification  of  individualized  substrate  targets,  accord-
ing  to different  types  of  AF  in specific-patients,  and  its
elimination  (or  modulation)  with  the adequate  energy
source  depends  on  the  emerging  advanced  mapping  tech-
nique  systems  and  correct  interpretation  of  the atrial
electrophysiological  information.  Clearly,  we  all  need  fur-
ther  investigation  to  find  out  whether  research  teams  are
flowing  in  the best  direction.
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